Regencell Bioscience Holdings Ltd

NASDAQ RGC

Download Data

Regencell Bioscience Holdings Ltd Tangible Book Value per Share 3 year CAGR for the Trailing 12 Months (TTM) ending September 19, 2024

Regencell Bioscience Holdings Ltd Tangible Book Value per Share 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 19, 2024. Tangible book value per share represents the shareholders' equity (tangible) minus goodwill and intangible assets divided by the weighted average number of outstanding shares. It provides the value of tangible assets per share owned by the shareholders. This ratio helps investors assess the tangible asset value relative to the number of shares outstanding. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email